What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Surgery
Her primary scientific interests are in Multiple myeloma, Internal medicine, Surgery, Thalidomide and Bortezomib.
Her research in Multiple myeloma intersects with topics in Radiology, Dexamethasone and Pharmacology.
Her work in Internal medicine covers topics such as Oncology which are related to areas like Refractory and Stem cell.
Her studies deal with areas such as Adverse effect and Cause of death as well as Surgery.
Her Thalidomide research includes elements of Randomized controlled trial and Urology.
Her Bortezomib research is multidisciplinary, incorporating perspectives in Proteasome inhibitor, Cancer research, Standard treatment, Leukemia and Autologous transplantation.
Her most cited work include:
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial (592 citations)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (505 citations)
What are the main themes of her work throughout her whole career to date?
Internal medicine, Multiple myeloma, Oncology, Bortezomib and Thalidomide are her primary areas of study.
The various areas that Sonja Zweegman examines in her Internal medicine study include Gastroenterology and Surgery.
Her Multiple myeloma study incorporates themes from Newly diagnosed, Dexamethasone and Cancer research.
Sonja Zweegman has researched Bortezomib in several fields, including Proteasome inhibitor, Proteasome and Pharmacology.
Her Thalidomide research incorporates themes from Regimen, Randomized controlled trial, Maintenance therapy and Prednisone.
Her biological study spans a wide range of topics, including Adverse effect, Progression-free survival and Clinical trial, Phases of clinical research.
She most often published in these fields:
- Internal medicine (52.49%)
- Multiple myeloma (46.61%)
- Oncology (24.43%)
What were the highlights of her more recent work (between 2018-2021)?
- Multiple myeloma (46.61%)
- Internal medicine (52.49%)
- Oncology (24.43%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Daratumumab and Cancer research.
Her Multiple myeloma research includes themes of Clinical trial, Intensive care medicine and Immunotherapy.
Her study involves Newly diagnosed, Dexamethasone, Transplantation, Myelofibrosis and Thalidomide, a branch of Internal medicine.
Her work in the fields of Oncology, such as Autologous stem-cell transplantation, intersects with other areas such as In patient.
She has included themes like Antibody, CD38, Cytotoxic T cell, Chimeric antigen receptor and Bone marrow in her Cancer research study.
Sonja Zweegman focuses mostly in the field of Lenalidomide, narrowing it down to matters related to Maintenance therapy and, in some cases, Placebo.
Between 2018 and 2021, her most popular works were:
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial (84 citations)
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study (58 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
Her primary scientific interests are in Multiple myeloma, Internal medicine, Daratumumab, Transplantation and Oncology.
Her Multiple myeloma research is multidisciplinary, relying on both Disease and Intensive care medicine.
Sonja Zweegman works mostly in the field of Daratumumab, limiting it down to topics relating to Cancer research and, in certain cases, Immunotherapy, Ex vivo, Bone marrow and Chimeric antigen receptor.
She combines subjects such as Ixazomib, Systematic review and Radiology with her study of Transplantation.
Her research integrates issues of Meta-analysis, Hematopoietic stem cell transplantation and Hazard ratio, Confidence interval in her study of Oncology.
Her Thalidomide study combines topics from a wide range of disciplines, such as Median follow-up and Standard treatment.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
